Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

State Of The Art Functional Imaging In Sickle Cell Disease

NCT01137721
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 19 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
5 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 7 more
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
Conditions
Anemia, Sickle Cell
Interventions
SANGUINATE, Placebo
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Hollywood, Florida • Tampa, Florida • Baltimore, Maryland + 5 more
Conditions
Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Wilmington, Delaware • Atlanta, Georgia + 6 more
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Conditions
Sickle Cell Disease
Interventions
Songwriting intervention (active music therapy)
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Conditions
Sickle Cell Disease
Interventions
HABIT Intervention, Standard of Care, Education materials
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Manhasset, New York • New York, New York • The Bronx, New York + 1 more
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
Interventions
Fludarabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Anemia, Sickle Cell
Interventions
Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 7 more
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Crovalimab, Eculizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Columbus, Ohio
Conditions
Sickle Cell Disease, Graft Versus Host Disease
Interventions
Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil
Drug · Procedure
Lead sponsor
Monica Bhatia
Other
Eligibility
3 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more
Conditions
Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions
Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine
Drug
Lead sponsor
Carelon Research
Other
Eligibility
1 Year to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Houston, Texas
Conditions
Anemia, Sickle Cell
Interventions
Cogmed RM
Behavioral
Lead sponsor
Steven J. Hardy
Other
Eligibility
7 Years to 16 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Conditions
Sickle Cell Disease
Interventions
nula-cel Drug Product
Genetic
Lead sponsor
Kamau Therapeutics
Industry
Eligibility
12 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • St Louis, Missouri + 1 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Acupressure in Patients With Sickle Cell Disease

NCT06511453
Conditions
Sickle Cell Disease
Interventions
Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand)
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Irvine, California • Indianapolis, Indiana
Conditions
Sickle Cell Disease, Thalassemia, Pediatric Cancer
Interventions
Red Blood Cell (RBC) Transfusion
Biological
Lead sponsor
Westat
Other
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
Conditions
Sickle Cell Disease, Antibiotics
Interventions
Rifaximin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Valhalla, New York
Completed Phase 2 Interventional Results available

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631
Conditions
Sickle Cell Anemia
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more